Curing all patients with acute promyelocytic leukemia: are we there yet? Review uri icon

Overview

abstract

  • The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

publication date

  • December 1, 2011

Research

keywords

  • Leukemia, Promyelocytic, Acute

Identity

PubMed Central ID

  • PMC4021483

Scopus Document Identifier

  • 81255177098

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2011.10.002

PubMed ID

  • 22093584

Additional Document Info

volume

  • 25

issue

  • 6